Fate Therapeutics/FATE

$6.98

0.43%
-
1D1W1MYTD1YMAX

About Fate Therapeutics

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of programmed cellular immunotherapies for patients with cancer and autoimmune disorders. It uses human induced pluripotent stem cells (iPSCs) generated from its iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The Company is advancing a pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted natural killer (NK) and T-cell product candidates. The Company's product pipeline includes FT576, FT819, FT825 and FT522. Its FT576, is an iPSC-derived, B-cell maturation antigen (BCMA)-targeted CAR NK cell product candidate for the treatment of multiple myeloma. Its FT819, is an iPSC-derived CAR T-cell therapy candidate, which is in Phase I study for the treatment of adult patients with relapsed / refractory B-cell malignancies, including B-cell lymphoma and chronic lymphocytic leukemia.

Ticker

FATE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

John Wolchko

Employees

181

Headquarters

San diego, United States

FATE Metrics

BasicAdvanced
$686.27M
Market cap
-
P/E ratio
-$1.77
EPS
1.66
Beta
-
Dividend rate

What the Analysts think about FATE

Analyst Ratings

Majority rating from 20 analysts.
Hold

Price Targets

Average projection from 15 analysts.
2.72% upside
High $12.00
Low $2.00
$6.98
Current price
$7.17
Average price target

FATE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2,373.68% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$1.9M
111.11%
Net income
$-45.1M
-14.42%
Profit margin
-2,373.68%
-59.46%

FATE Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 13.9%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.19
-$0.54
-$0.46
-$0.45
-
Expected
-$0.62
-$0.59
-$0.57
-$0.52
-$0.52
Surprise
-69.5%
-8.22%
-19.28%
-13.9%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Fate Therapeutics stock

Buy or sell Fate Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing